Is there any treatment available for dry AMD? 

Age related macular degeneration (AMD) is the most common cause of vision loss in the United Kingdom, and the dry form of the condition accounts for approximately 80 to 90 percent of all cases. For many years, the clinical consensus has been that while the “wet” form of the disease can be managed with injections, the “dry” form remains largely untreatable. As of early 2026, this remains the primary clinical reality for patients within the National Health Service (NHS). There is currently no pharmaceutical cure or surgical procedure available on the standard UK medical pathway that can stop the progression of dry AMD or restore vision once it has been lost. However, the field of retinal research is moving at an unprecedented pace, with new technologies, specialized nutritional protocols, and emerging therapies for advanced dry AMD (geographic atrophy) offering a more proactive approach to management than ever before. 

What We’ll Discuss in This Article 

• The status of pharmacological treatments for dry AMD in the UK. 

• The role of AREDS2 nutritional supplements in managing intermediate stages. 

• Why the MHRA and European regulators have recently rejected certain GA treatments. 

• Breakthroughs in electronic retinal implants and bionic vision. 

• How lifestyle modifications act as the primary “treatment” for early stages. 

• The future of gene and stem cell therapies currently in UK clinical trials. 

• Support systems and low vision services for maintaining independence. 

The current pharmaceutical landscape in the UK 

The search for a medication that can “dry up” the waste deposits known as drusen or regenerate the thinning layers of the macula has proven to be one of the greatest challenges in modern ophthalmology. Unlike wet AMD, which is driven by a single protein (VEGF), dry AMD is a complex, multi factorial disease involving inflammation, oxidative stress, and the gradual failure of the eye’s waste disposal systems. Because there is no single “target” for a drug, there is currently no licensed medication available in the UK that a doctor can prescribe to treat early or intermediate dry AMD. 

In 2026, the focus of UK clinical management is on monitoring and prevention. Optometrists and ophthalmologists focus on identifying the condition early and providing guidance on how to slow its progression. While it is frustrating for patients to be told there is “no treatment,” it is important to understand that this refers to a medical cure. There are still many evidence based steps that can be taken to protect the remaining vision and delay the onset of the more severe stages of the disease. You can find the latest NHS overview of AMD management for the current year. 

New treatments for Geographic Atrophy: The 2026 update 

The advanced stage of dry AMD is known as geographic atrophy (GA), where large patches of the macula have permanently wasted away. In recent years, two significant drugs were developed in the United States to target the “complement system,” a part of the immune system that is overactive in people with GA. These drugs, Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), were designed to slow down the rate at which these patches of vision loss grow. 

However, for patients in the United Kingdom, the situation is different. As of early 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) and European regulators have been cautious about approving these medications. While these drugs successfully slowed the growth of retinal lesions in clinical trials, regulators expressed concerns that they did not provide a “meaningful benefit” to the patient’s daily life or actual visual acuity during the study periods. Furthermore, there was an identified risk of these treatments causing a transition to wet AMD. Consequently, these specific injections are not currently a standard part of the NHS treatment pathway, though they remain under constant review as more long-term data becomes available. 

The role of AREDS2 nutritional supplements 

While there is no drug for dry AMD, there is strong clinical evidence from the Age-Related Eye Disease Studies (AREDS and AREDS2) that a specific combination of vitamins and minerals can help some patients. This formula is primarily recommended for people with “intermediate” dry AMD in both eyes, or those with advanced AMD in only one eye. The formula includes Vitamin C, Vitamin E, Zinc, Copper, Lutein, and Zeaxanthin. 

In the UK, NHS England does not typically recommend these supplements for routine prescription because they are classified as “food supplements” rather than medications. However, many UK ophthalmologists suggest that patients purchase these over the counter as part of a proactive management plan. It is important to note that these supplements do not “fix” the vision loss, but they have been shown to reduce the risk of progressing to the advanced stages of the disease by approximately 25 percent. The Royal College of Ophthalmologists provides detailed guidance on the use of these specific nutritional protocols. 

Lifestyle modifications as primary management 

In the absence of a pharmaceutical cure, lifestyle changes are considered the most effective “treatment” for early dry AMD. In the United Kingdom, the clinical focus is on four main pillars: smoking cessation, diet, blood pressure control, and UV protection. Smoking is the single most dangerous modifiable risk factor, as it doubles the rate of vision loss and increases the risk of transitioning to wet AMD. 

A diet rich in dark, leafy green vegetables like kale and spinach provides the macula with the natural pigments it needs to filter out harmful blue light. Additionally, protecting the eyes from the sun with UV 400 rated sunglasses is essential for reducing the oxidative stress on the retinal cells. While these steps may seem simple, they are the only clinically proven methods to support the health of the macula and preserve vision for as long as possible. Many patients find that taking these active steps provides a sense of control over a condition that can otherwise feel overwhelming. 

Breakthroughs in electronic eye implants 

For those who have already lost significant central vision to advanced dry AMD, the most exciting developments are in the field of “bionic” vision. In a groundbreaking UK clinical trial led by Moorfields Eye Hospital, an electronic microchip was implanted under the retina of patients with geographic atrophy. This chip works in conjunction with a pair of specialized glasses containing a camera. The camera captures images and beams them to the chip, which then stimulates the remaining healthy cells in the retina. 

The results of these trials have been remarkable, with 84 percent of participants regaining the ability to read letters, numbers, and words using this prosthetic vision. While this technology is still in the trial phase and is not yet widely available on the NHS, it represents a significant shift in the treatment of dry AMD. For the first time, researchers are finding ways to “bypass” the damaged macula and restore functional sight to those in the latest stages of the disease. You can follow the progress of these research project updates through Moorfields. 

Future horizons: Gene and stem cell therapy 

Beyond implants, the UK is a world leader in gene and stem cell research for macular conditions. Gene therapy aims to inject a harmless virus into the eye that carries “instructions” for the retinal cells to produce protective proteins. This could effectively turn the eye into a “medicine factory,” preventing the cellular breakdown that causes dry AMD. Several Phase 2 and Phase 3 trials are currently active in the UK for this technology. 

Stem cell therapy involves growing new retinal pigment epithelium (RPE) cells in a laboratory and “patching” them onto the damaged area of the macula. The London Project to Cure Blindness has already demonstrated that this can be done successfully in small groups of patients. While these treatments are not yet available to the public, they suggest that a future where dry AMD can be “repaired” is within reach. Most UK specialists believe that within the next decade, these biological therapies will transform the way we manage the dry form of the disease. 

Summary of Dry AMD Management Options for 2026 

Management Type	Availability in UK	Clinical Goal
Pharmacological Cure	None currently licensed	N/A
AREDS2 Supplements	Over-the-counter	Slow progression in intermediate cases
GA Injections (Syfovre)	Rejected by MHRA (2025/26)	Slow lesion growth (Not for vision gain)
Retinal Implants	Clinical trials (Moorfields)	Restore reading vision in late-stage GA
Gene Therapy	Clinical trials	Stop cellular degeneration at source
Lifestyle Changes	Universal recommendation	Reduce oxidative stress and inflammation
Low Vision Aids	Available through NHS	Maximize remaining sight and independence

The importance of low vision services 

When medical treatments are not an option, the focus of the NHS turns to rehabilitation. Low vision services in the UK are designed to help patients make the most of their peripheral vision to compensate for the loss of central sight. This involves an assessment by a specialist who can provide high powered magnifiers, electronic reading devices, and training in “eccentric viewing”—a technique where patients learn to look slightly away from an object to see it more clearly. 

Maintaining independence is the primary goal of these services. By using large print books, audiobooks, and specialized lighting at home, many people with advanced dry AMD continue to live active and fulfilling lives. In the UK, a referral to a low vision clinic is a standard part of the care pathway once vision reaches a certain threshold. These services provide the practical “treatment” that helps patients navigate the challenges of daily life with central vision loss. Detailed support is available through the RNIB’s guide to living with macular degeneration. 

Conclusion 

There is currently no pharmacological treatment available on the NHS that can cure or stop dry age-related macular degeneration. While treatments for the advanced “geographic atrophy” stage have been developed abroad, they have not yet met the strict requirements for clinical benefit and safety in the UK. However, for those with intermediate AMD, specialized supplements can offer protection, and for those in the earliest stages, lifestyle changes remain the most powerful tool for sight preservation. With the emergence of electronic implants and gene therapies in UK clinical trials, the outlook for future dry AMD management is more hopeful than ever. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot 

This article provides an up-to-date overview of the dry AMD treatment landscape in the United Kingdom for 2026. It was written by the Medical Content Team and reviewed by Dr. Stefan, a UK trained physician with extensive experience in internal medicine and geriatric care. All information is strictly aligned with the current clinical standards and regulatory decisions made by the NHS, NICE, and the MHRA to ensure the highest level of patient safety and accuracy.